Abstract
During the first 6 years of the Program of Genetic Counselling in Cancer of Valencia (eastern Spain), 310 mutations (155 in BRCA1 and 155 in BRCA2) in 1,763 hereditary breast (BC) and ovarian cancer (OC) families were identified. Of the mutations found 105 were distinct (53 in BRCA1 and 52 in BRCA2), eight new and 37 recurrent. Two of the novel mutations were frame-shift placed in exons 2 and 11 of BRCA1 and the remaining six were placed in BRCA2; four frame-shift (three in exon 11 and one in exon 23), one deletion of the entire exon 19 and one in the intervening sequence of exon 22. The BRCA1 mutations with higher recurrence were c.66_68delAG, c.5123C > A, c.1961delA, c.3770_3771delAG and c.5152+5G > A that covered 45.2 % of mutations of this gene. The age of onset of BCs of c.68_69delAG mutation carriers occurs later than for the other recurrent mutations of this gene (45 vs. 37 years; p = 0.008). The BRCA2 mutations with higher recurrence were c.9026_9030delATCAT, c.3264insT and c.8978_8991del14 which represented 43.2 % of all mutations in this gene, being the most recurrent mutation by far c.9026_9030delATCAT that represents 21.3 % of BRCA2 mutations and 10.6 % of all mutations. Probands with family histories of BC and OC, or OC and/or BC in at least two first degree relatives, were the more likely to have BRCA1/BRCA2 mutations (35.2 % of the total mutations). And that most BRCA1mutations (73.19 % mutations) occurred in probands with early-onset BC or with family history of OC.
This is a preview of subscription content, log in via an institution to check access.
References
Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71
Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792
Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963–970
Laitman Y, Simeonov M, Herskovitz L et al (2012) Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. Breast Cancer Res Treat 133:1153–1157
Thorlacius S, Olafsdottir G, Tryggvadottir L et al (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13:117–119
Li Wen-Feng, Zhen Hu, Rao NY et al (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110:99–109
Kwong A, Ng EKO, Wong CLP et al (2012) Identification of BRCA1/2 Founder mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. PLoS One 7(9):e43994. doi:10.1371/journal.pone.0043994
Neuhausen SL (1999) Ethnic differences in cancer risk resulting from genetic variation. Cancer 86:2575–2582
Szabo CI, King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60:1013–1020
De la Hoya M, Osorio A, Godino J et al (2002) Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 97:466–471
Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical Characteristics of Individuals with Germline Mutations in BRCA1 and BRCA2: analysis of 10,000 Individual. J Clin Oncol 20:1480–1490
Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A (2001) Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93:1215–1223
Aretini P, D’ Andrea E, Pasini E et al (2003) Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutations. Breast Cancer Res Treat 81:71–79
Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast cancer linkage consortium. Am J Hum Genet 62:676–689
Cáncer Hereditario de Mama y Ovario (2008) En: Guía de Practica Clínica en Cáncer hereditario. Plan Oncológico Comunidad Valenciana. Generalitat. Conselleria de Sanitat, pp 32–55. Generalitat Valenciana
World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects (2004) Disponible en: http://www.wma.net/e/policy/pdf/17c.pdf
The Breast Cancer Information Core Database, BIC. http://research.nhgri.nih.gov/bic/Member/index.shtml
Ganguly A, Rock MJ, Prockop DJ (1993) Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA 90:10325–10329
Esteban Cardeñosa E, Bolufer Gilabert P, Palanca Suela S et al (2008) Mutaciones de BRCA1 y BRCA2 en familias estudiadas en el Programa de Consejo Genético en el Cáncer de la Comunidad Valenciana. Med Clin (Barc) 130(4):121–126
Schouten JP, McElgunn CJ, Waaijer R et al (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57
den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15:7–12
UMD (Universal mutation database): http://www.umd.be
Human Variation: Search, Annotate, Submit: http://www.ncbi.nlm.nih.gov/SNP/tranSNP/tranSNP.cgi?rm
Neuhausen SL, Mazoyer S, Friedman L et al (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 58:271–280
Díez O, Osorio A, Durán M et al (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22:301–312
Beristain E, Martınez-Bouzas C, Guerra I et al (2007) Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling. Breast Cancer Res Treat 106:255–262
Miramar MD, Calvo MT, Rodriguez A et al (2008) Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1. Breast Cancer Res Treat 112:353–358
Diez O, Gutierrez-Enrıquez S, Balmaña J (2010) Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing. Fam Cancer 9:187–191
Infante M, Duran M, Esteban-Cardeñosa E et al (2006) High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain). J Hum Genet 51:611–617
Neuhausen SL, Godwin AK, Gershoni-Baruch R et al (1998) Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 62:1381–1388
Llort G, Yagüe C, Peris M et al (2002) Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain. Hum Mutat 19:307
Esteban-Cardeñosa E, Bolufer-Gilabert P, Palanca-Suela S et al (2008) Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain. Breast Cancer Res Treat 112:69–73
Esteban-Cardeñosa E, Bolufer-Gilabert P, de Juan-Jimenez I et al (2010) Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population. Breast Cancer Res Treat 121:257–260
Vega A, Campos B, Bressac-De-Paillerets B et al (2001) The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 17:520–521
Al-Mulla F, Bland JM, Serratt D et al (2009) Age-dependent penetrance of different germline mutations in the BRCA1 gene. J Clin Pathol 62:350–356
Varizi SA, Krumroy LM, Paul Elson P et al (2001) Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 7:1937–1945
Acknowledgments
We should express here our gratitude for the good work and dedication to the laboratory technicians Virginia González, Teresa Barrachina and Gemma Pérez, the last granted by the Instituto de Investigación Sanitaria del H.U. La Fe.
Conflict of interest
None to be declared.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study is conducted on behalf of the Group for Assessment for Hereditary Cancer of Valencian Community.
Rights and permissions
About this article
Cite this article
de Juan Jiménez, I., García Casado, Z., Palanca Suela, S. et al. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence. Familial Cancer 12, 767–777 (2013). https://doi.org/10.1007/s10689-013-9622-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-013-9622-2